FDA approves Novo Nordisk's new Wegovy® HD injection, delivering the highest weight loss to date for a Wegovy® injection, adding to its already expansive clinical profile

Q: What weight loss did NVO report for Wegovy HD (7.2 mg) in the STEP UP trial?

Wegovy HD achieved about 21% average weight loss at 72 weeks in an efficacy scenario. According to the company, the treatment-regimen analysis showed ~19% average weight loss regardless of treatment persistence, with 31.2% of patients reaching ≥25% loss.

Q: When will Wegovy HD (NVO) be available for patients in the US?

Wegovy HD is planned to be available in April 2026 through major pharmacies and channels. According to the company, access will include 70,000+ pharmacies, select telehealth providers, NovoCare Pharmacy, GoodRx, and other patient access programs.

Q: What safety risks did Novo Nordisk highlight for Wegovy HD (NVO)?

Common adverse reactions included nausea, vomiting, and dysesthesia , reported at higher rates with HD. According to the company, events related to altered skin sensation occurred in 22% of Wegovy HD patients versus 6% with 2.4 mg and 0.3% with placebo.

Q: Who is eligible to start Wegovy HD (NVO) 7.2 mg for obesity treatment?

Wegovy HD is for adults with obesity who have tolerated 2.4 mg for at least 4 weeks and need further weight reduction. According to the company, it should be used with reduced calorie diet and increased physical activity as adjunct therapy.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

Novo Nordisk (NVO) announced FDA approval of Wegovy HD (semaglutide) 7.2 mg injection on March 19, 2026, for adults with obesity who have tolerated 2.4 mg and need additional weight reduction.

STEP UP showed ~21% average weight loss (efficacy estimand) at 72 weeks and 31.2% of patients reached ≥25% weight loss; common adverse reactions included nausea and dysesthesia (22% in the HD arm).

Positive

Average weight loss ~21% at 72 weeks (efficacy estimand)
31.2% of patients achieved ≥25% weight loss
Expanded label adds a higher-dose option to existing Wegovy formulations
Availability planned in April through major pharmacies and channels

Negative

Dysesthesia and altered skin sensation reported in 22% of Wegovy HD patients
Higher rates of nausea and vomiting versus placebo
Wegovy HD requires prior tolerance of 2.4 mg, limiting immediate use

News Market Reaction – NVO

-0.99%

1 alert

-0.99% News Effect

On the day this news was published, NVO declined 0.99%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Weight loss (efficacy estimand): 20.7% at 72 weeks Weight loss (treatment estimand): 18.8% at 72 weeks ≥25% weight loss rate: 31.2% +5 more

8 metrics

Weight loss (efficacy estimand) 20.7% at 72 weeks Average reduction with Wegovy® HD 7.2 mg if all patients stayed on treatment

Weight loss (treatment estimand) 18.8% at 72 weeks Average reduction with Wegovy® HD regardless of treatment persistence

≥25% weight loss rate 31.2% STEP UP trial participants on Wegovy® HD achieving ≥25% weight loss

Trial duration 72 weeks STEP UP study evaluating Wegovy® 7.2 mg vs 2.4 mg and placebo

Sample size 1,407 adults Adults with obesity (BMI ≥30 kg/m²) without diabetes in STEP UP

Baseline weight (HD arm) 248 lb Mean baseline body weight for Wegovy® 7.2 mg and placebo groups

Altered skin sensation events 22% vs 6% vs 0.3% Events in Wegovy® HD vs 2.4 mg vs placebo arms in STEP UP

Pharmacies carrying Wegovy 70,000+ US pharmacies where Wegovy® (including HD) will be available

Market Reality Check

Price: $36.48 Vol: Volume 26,177,848 is near...

normal vol

$36.48 Last Close

Volume Volume 26,177,848 is near the 20-day average of 26,759,609 (relative volume 0.98). normal

Technical Price 37.45 trades below the 200-day MA at 55.25 and is 54.64% under the 52-week high of 82.57.

Peers on Argus

NVO fell 2.55% while key peers AZN, NVS, MRK, ABBV, and JNJ also declined, but n...

NVO fell 2.55% while key peers AZN, NVS, MRK, ABBV, and JNJ also declined, but no peers appeared in the momentum scanner, suggesting a stock-specific move rather than a coordinated sector surge.

Previous Fda approval Reports

3 past events · Latest: Jun 26 (Positive)

Same Type Pattern 3 events

Date	Event	Sentiment	Move	Catalyst
Jun 26	Wegovy access/offer	Positive	+0.5%	New collaboration and savings offer to expand access to FDA-approved Wegovy.
May 22	Pricing & access move	Positive	-0.0%	Initiatives and pricing offers as FDA ban on mass compounding takes effect.
Mar 05	NovoCare pharmacy launch	Positive	+3.8%	Launch of NovoCare® Pharmacy to lower Wegovy cost and improve home delivery.

Pattern Detected

Past Wegovy-related FDA/access announcements with the same tag showed modest positive or flat moves around approval and access initiatives.

Recent Company History

Recent Wegovy-related FDA approval and access news has focused on improving affordability and reaching more patients. In March 2025, NovoCare® Pharmacy cut all Wegovy® doses to $499/month, with a 3.84% price gain. In May and June 2025, new pricing offers and collaborations supported access and combated illegal compounded products, with 24h moves of -0.04% and 0.52%. Today’s higher-dose approval extends this pattern of label and access expansion.

Historical Comparison

+1.4% avg move · In the past year, three Wegovy-related FDA/access announcements averaged a 1.44% 24h move. Today’s F...

fda approval

+1.4%

Average Historical Move fda approval

In the past year, three Wegovy-related FDA/access announcements averaged a 1.44% 24h move. Today’s FDA approval of Wegovy® HD fits the same label/access expansion theme but with a weaker immediate price reaction.

Historical same-tag events show a progression from resolving Wegovy® shortages to building dedicated pharmacy channels, then layered pricing and collaboration programs; today’s Wegovy® HD approval adds a higher-dose option to that expanding access and label story.

Market Pulse Summary

This announcement adds a higher-dose Wegovy® HD option with compelling STEP UP data, including mean ...

Analysis

This announcement adds a higher-dose Wegovy® HD option with compelling STEP UP data, including mean weight loss of up to 20.7% and 31.2% of patients achieving ≥25% loss. It builds on prior Wegovy® initiatives that improved access and pricing. Investors may track uptake across 70,000+ US pharmacies, safety trends such as the 22% altered skin sensation rate, and how the new dose integrates with existing 2.4 mg and oral formulations.

Key Terms

semaglutide, glp-1, bmi, placebo, +4 more

8 terms

semaglutide medical

"Wegovy® HD (semaglutide) injection 7.2 mg, which demonstrated substantial weight loss"

Semaglutide is a medication originally developed to help manage blood sugar levels in people with diabetes, but it also promotes weight loss. It works by mimicking a natural hormone that helps control appetite and insulin release. For investors, its potential to influence healthcare and weight management markets makes it a significant product in the pharmaceutical industry.

glp-1 medical

"indications not available with other GLP-1 weight loss medicines"

GLP-1 (glucagon-like peptide-1) is a natural hormone in the body that helps regulate blood sugar levels and appetite. Its significance to investors lies in its role as the basis for a class of medications that address conditions like type 2 diabetes and obesity, which are large and growing markets. Advances or investments in GLP-1-based treatments can signal opportunities in healthcare innovation and potentially impact pharmaceutical companies’ growth.

bmi medical

"1,407 adults with obesity (BMI 30 kg/m2 or greater), without diabetes"

Body mass index (BMI) is a simple number calculated from a person’s weight and height that classifies them as underweight, normal weight, overweight, or obese; think of it as a quick ratio like miles per gallon for body size. Investors watch BMI because shifts in population averages influence demand for healthcare services, drugs, medical devices, and insurance costs, and they can signal longer-term trends in workforce health and public spending.

placebo medical

"evaluated the efficacy and safety of once-weekly Wegovy® 7.2 mg compared to placebo"

A placebo is an inactive pill, injection or procedure that looks and feels like the real treatment but contains no therapeutic ingredient, often called a sugar pill. Investors care because comparing a drug to a placebo reveals whether observed benefits come from the medicine itself or from expectation; clear superiority over placebo reduces regulatory and commercial risk, much like a blind taste test proves a new recipe really tastes better.

adverse reactions medical

"The most common adverse reactions reported with Wegovy® HD were nausea, vomiting"

Adverse reactions are harmful or unintended effects people experience after using a medicine, vaccine, medical device, or treatment; think of them as unexpected problems that show up when a product is used as intended. Investors care because these reactions can trigger regulatory warnings, safety reviews, recalls, reduced sales, or legal costs—similar to how widespread product defects can damage a company’s reputation and future earnings.

dysesthesia medical

"dysesthesia, constipation, abdominal pain, fatigue, headache, dizziness"

Dysesthesia is a medical condition in which people feel unpleasant, abnormal sensations—such as burning, electric shocks, itching, or numbness—that can occur without any external cause or from a light touch. For investors, reports of dysesthesia matter because they signal potential safety or tolerability issues for drugs, medical devices, or treatments; such side effects can affect regulatory approval, labeling, market acceptance, and ultimately a product’s commercial prospects, similar to a consumer product gaining a reputation for causing discomfort.

hyperesthesia medical

"such as sensitive skin, hyperesthesia, dysesthesia and paresthesia were reported"

An increased sensitivity to touch, sound, light or other sensations, where normal stimuli feel unusually strong or painful — like a volume knob on perception turned up too high. Investors track hyperesthesia because it can be a key side effect in clinical trials, influence drug labeling, regulatory decisions and market acceptance, and thus affect a treatment’s commercial prospects and a company’s valuation.

paresthesia medical

"hyperesthesia, dysesthesia and paresthesia were reported by a higher proportion"

Paresthesia is an abnormal skin sensation such as tingling, numbness, burning or “pins and needles,” often described like a hand or foot that has temporarily “fallen asleep.” In financial and clinical reporting, mention of paresthesia flags a potential safety or tolerability issue with a drug or device that can influence regulatory review, prescribing decisions and investor confidence—similar to a dashboard warning that prompts closer scrutiny.

AI-generated analysis. Not financial advice.

03/19/2026 - 12:04 PM

Average weight loss of ~21% at 72 weeks in adults with obesity if all patients stayed on treatment^* with Wegovy^® HD (~19% regardless of whether patients stayed on treatment^**) in the STEP UP trial¹
In the STEP UP trial, about one in three trial participants taking Wegovy^® HD achieved 25% weight loss or higher¹
This approval for Wegovy^® further expands its already robust label inclusive of multiple formulations, including Wegovy^® pill, and indications not available with other GLP-1 weight loss medicines

PLAINSBORO, N.J., March 19, 2026 /PRNewswire/ -- Novo Nordisk today announced US Food and Drug Administration (FDA) approval of a new higher dose of Wegovy^®, Wegovy^® HD (semaglutide) injection 7.2 mg, which demonstrated substantial weight loss in adults with obesity in the STEP UP trial.^1,2 Wegovy^® HD can be used along with a reduced calorie diet and increased physical activity to help adults with obesity lose weight and keep it off, provided they have tolerated the 2.4 mg dosage for at least 4 weeks and additional weight reduction is clinically indicated. This new update supplements the existing Wegovy^® label, which also has distinct indications for Wegovy^® not offered by any other GLP-1 medication for weight loss.²

"We are excited to bring Wegovy^® HD injection to adults with obesity who are looking for powerful weight loss, as no other weight loss medicine has been studied to show superiority to Wegovy^® HD," said Jamey Millar, executive vice president, US Operations of Novo Nordisk. "In addition to significant weight loss, Wegovy^® is the only GLP-1 for adults with obesity that is proven to reduce the risk of events such as stroke, heart attack, or cardiovascular death in those who also have known heart disease. Today's milestone expands the strong clinical profile of Wegovy^® that includes multiple indications that no other GLP-1 for weight loss can claim."

Prior to this approval, the highest approved dose of Wegovy^® injectable for weight loss was 2.4 mg, which is also indicated, along with a reduced calorie diet and increased physical activity, to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight.²

The FDA approval of Wegovy^® HD is based on the results of the STEP UP trial program, which included STEP UP, a 72-week study which evaluated the efficacy and safety of once-weekly Wegovy^® 7.2 mg compared to placebo and Wegovy^® 2.4 mg, as an adjunct to lifestyle intervention in 1,407 adults with obesity (BMI 30 kg/m² or greater), without diabetes.^1,3

STEP UP Trial Results (at 72 weeks^{1, 2})
		Wegovy^® injection 7.2 mg	Wegovy^® injection 2.4 mg	Placebo
Average weight reduction¹	If all patients stayed on treatment (Efficacy estimand^*)	~21% (20.7%)	~18% (17.5%)	~2% (2.4%)
Average weight reduction¹	Analysis of all patients regardless of whether they stayed on treatment² (Treatment regimen estimand^**)	~19% (18.8%)	~16% (15.5%)	~4% (3.9%)
	Percent of patients who achieved 25% or more weight loss^**	31.2 %	15.3 %	0 %

Based on a mean baseline body weight of 248 lb. for Wegovy^® injection 7.2 mg and placebo groups, and 257 lb. for the Wegovy^® 2.4 mg group.

The most common adverse reactions reported with Wegovy^® HD were nausea, vomiting, dysesthesia, constipation, abdominal pain, fatigue, headache, dizziness, hair loss and flatulence. In clinical trials, dysesthesia was reported at a higher rate with Wegovy^® HD compared to Wegovy^® 2.4 mg and placebo.²Events related to a clinical picture of altered skin sensation such as sensitive skin, hyperesthesia, dysesthesia and paresthesia were reported by a higher proportion of participants, and at a higher rate, in the Wegovy^®HD arm (22%), compared to treatment with Wegovy^®2.4 mg (6%) and placebo (0.3%).²

"Wegovy^® HD represents an important new tool in obesity management, allowing clinicians to better tailor treatment strategies and help improve outcomes," said W. Timothy Garvey, MD, professor of medicine and director of the Diabetes Research Center at the University of Alabama at Birmingham. "The weight loss demonstrated with Wegovy^® HD could reshape healthcare professionals' expectations about what outcomes are possible for their patients with Wegovy^®."

Wegovy^® HD will be available in April through all channels where patients can access Wegovy^® including 70,000 plus pharmacies in the US like CVS and Costco, select telehealth providers, NovoCare^® Pharmacy, GoodRx, and others. Additional information on coverage and savings options for eligible patients, including other programs designed to help reduce out-of-pocket costs, will also be available at that time.

^* Based on the efficacy estimand: estimated efficacy in an idealized scenario in which all patients stayed on treatment and took no other weight loss therapies.
^** Based on the treatment regimen estimand: treatment effect regardless of whether patients stayed on treatment or took other weight loss therapies.

About the STEP UP trial
STEP UP was a phase 3b 72-week randomized, double-blinded, placebo-controlled and active-controlled superiority trial designed to evaluate the efficacy and safety of semaglutide injection 7.2 mg compared to semaglutide injection 2.4 mg and placebo as an adjunct to lifestyle intervention.¹ 1,407 adults with BMI ≥30 kg/m²without diabetes were included in the trial. The primary objective was to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss after 72 weeks with respect to the percentage change in body weight and the proportion of participants achieving weight loss of 5% or greater.¹ Select confirmatory secondary endpoints included number of participants achieving ≥10%, 15%, 20% and 25% weight loss, with semaglutide 7.2 mg vs placebo (and for greater than or equal to 20% and 25%, semaglutide 7.2 mg vs semaglutide 2.4 mg).¹ In total, 1,407 participants were randomized in a 5:1:1 ratio to receive once-weekly subcutaneous semaglutide 7.2 mg, 2.4 mg, or placebo, alongside lifestyle intervention, for 72 weeks.¹For those taking Wegovy^® HD, 89% achieved 5% or greater body weight loss versus 38% taking placebo (from a baseline body weight of 248 lb.).^**

About obesity
Obesity is a serious, chronic, progressive, and complex disease that requires long-term management.^4-6 One key misunderstanding is that this is a disease of just lack of willpower, when in fact there is underlying biology that may impede people with obesity from losing weight and keeping it off.^4,6 Obesity is influenced by a variety of factors, including genetics, social determinants of health, and the environment.^7,8

What is Wegovy^®?

Wegovy^®(semaglutide) injection is a prescription medicine used with a reduced-calorie diet and increased physical activity to:

reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight.
help adults and children aged 12 years and older with obesity, or some adults with excess weight (overweight) who also have weight-related medical problems to lose weight and keep the weight off.

Wegovy^® (semaglutide) tablets are a prescription medicine used with a reduced-calorie diet and increased physical activity to:

reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight.
help adults with obesity, or some adults with excess weight (overweight) who also have weight-related medical problems to lose weight and keep the weight off.

Wegovy^®contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines.

It is not known if Wegovy^® injection is safe and effective:

to reduce the risk of major cardiovascular events (death, heart attack, or stroke) in people under 18 years
to help children under 12 years of age lose weight and keep the weight off

It is not known if Wegovy^®tablets are safe and effective for use in people under 18 years of age.

Important Safety Information

What is the most important information I should know about Wegovy^®?
Wegovy^®may cause serious side effects, including:

Possible thyroid tumors, including cancer. Tell your healthcare provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In studies with rodents, Wegovy^®and other medicines that work like Wegovy^®caused thyroid tumors, including thyroid cancer. It is not known if Wegovy^®will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people
Do not use Wegovy^®if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

Do not use Wegovy^® if:

you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
you have had a serious allergic reaction to semaglutide or any of the ingredients in Wegovy^® injection or Wegovy^® tablets. See symptoms of serious allergic reaction in "What are the possible side effects of Wegovy^®?"

Before using Wegovy^®, tell your healthcare provider if you have any other medical conditions, including if you:

have or have had problems with your pancreas or kidneys
have type 2 diabetes and a history of diabetic retinopathy
are scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)
are pregnant or plan to become pregnant. Wegovy^®may harm your unborn baby. You should stop using Wegovy^®2 months before you plan to become pregnant
are breastfeeding or plan to breastfeed. Breastfeeding is not recommended during treatment with Wegovy^® tablets. It is not known if Wegovy^® when received through an injection passes into your breast milk

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Wegovy^®may affect the way some medicines work and some medicines may affect the way Wegovy^®works. Tell your healthcare provider if you are taking other medicines to treat diabetes, including sulfonylureas or insulin. Wegovy^®slows stomach emptying and can affect medicines that need to pass through the stomach quickly.

What are the possible side effects of Wegovy^®?
Wegovy^®may cause serious side effects, including:

inflammation of your pancreas (pancreatitis). Stop using Wegovy^®and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. Sometimes you may feel the pain from your abdomen to your back
gallbladder problems. Wegovy^®may cause gallbladder problems, including gallstones. Some gallstones may need surgery. Call your healthcare provider if you have symptoms, such as pain in your upper stomach (abdomen), fever, yellowing of the skin or eyes (jaundice), or clay-colored stools
increased risk of low blood sugar (hypoglycemia), especially those who also take medicines for diabetes such as insulin or sulfonylureas. This can be a serious side effect. Talk to your healthcare provider about how to recognize and treat low blood sugar and check your blood sugar before you start and while you take Wegovy^®. Signs and symptoms of low blood sugar may include dizziness or light-headedness, blurred vision, anxiety, irritability or mood changes, sweating, slurred speech, hunger, confusion or drowsiness, shakiness, weakness, headache, fast heartbeat, or feeling jittery
dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away
severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Wegovy^®. Tell your healthcare provider if you have stomach problems that are severe or will not go away
serious allergic reactions. Stop using Wegovy^®and get medical help right away, if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; or very rapid heartbeat
change in vision in people with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Wegovy^®
increased heart rate. Wegovy^®can increase your heart rate while you are at rest. Tell your healthcare provider if you feel your heart racing or pounding in your chest and it lasts for several minutes
food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Wegovy^® may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking Wegovy^® before you are scheduled to have surgery or other procedures

The most common side effects of Wegovy^®may include: nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, changes in skin sensations, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and hair loss.

Please click here for Prescribing Information including Boxed Warning and Medication Guide for Wegovy^®.

About Novo Nordisk
Novo Nordisk is a leading global health care company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a US presence spanning 40 years, Novo Nordisk US is headquartered in New Jersey and employs approximately 10,000 people across more than 10 manufacturing, R&D and corporate locations in eight states plus Washington, D.C. For more information, visit novonordisk-us.com, Facebook, Instagram, and X.

Contacts for further information

Media:
Liz Skrbkova (US) +1 609 917 0632 USMediaRelations@novonordisk.com	Ambre James-Brown (Global) +45 3079 9289 Globalmedia@novonordisk.com

Investors:
Frederik Taylor Pitter (US) +1 609 613 0568 fptr@novonordisk.com	Jacob Martin Wiborg Rode (Global) +45 3075 5956 jrde@novonordisk.com

Sina Meyer (Global) +45 3079 6656 azey@novonordisk.com	Christoffer Sho Togo Tullin (Global) +45 3079 1471 cftu@novonordisk.com

Max Ung (Global) +45 3077 6414 mxun@novonordisk.com	Alex Bruce (Global) +45 34 44 26 13 axeu@novonordisk.com

References:

Wharton S, Freitas P, Hjelmesæth J, et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025;13(11):949-963.
Wegovy^® (semaglutide) Prescribing Information. Plainsboro, NJ: Novo Nordisk Inc.
Lingvay I, Bergenheim S, Buse J, et al. Once-weekly semaglutide 7.2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025;13(11):935-948.
Kaplan LM, Golden A, Jinnett K, et al. Perceptions of barriers to effective obesity care: results from the national action study. Obesity. 2018;26(1):61–69.
Bray GA, Kim KK, Wilding JPH; World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017;18(7):715–723.
Garvey WT, Mechanick JI, Brett EM, et al. American association of clinical endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22 (Suppl 3):1–203.
Centers for Disease Control and Prevention. Adult obesity facts. Last accessed: March 2026. Available at: https://www.cdc.gov/obesity/adult-obesity-facts/index.html
Centers for Disease Control and Prevention. Risk Factors for Obesity. Last accessed: March 2026. Available at: https://www.cdc.gov/obesity/risk-factors/risk-factors.html.

View original content to download multimedia:https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-new-wegovy-hd-injection-delivering-the-highest-weight-loss-to-date-for-a-wegovy-injection-adding-to-its-already-expansive-clinical-profile-302718982.html

SOURCE NOVO NORDISK INC.

FAQ

What weight loss did NVO report for Wegovy HD (7.2 mg) in the STEP UP trial?

Wegovy HD achieved about 21% average weight loss at 72 weeks in an efficacy scenario. According to the company, the treatment-regimen analysis showed ~19% average weight loss regardless of treatment persistence, with 31.2% of patients reaching ≥25% loss.

When will Wegovy HD (NVO) be available for patients in the US?

Wegovy HD is planned to be available in April 2026 through major pharmacies and channels. According to the company, access will include 70,000+ pharmacies, select telehealth providers, NovoCare Pharmacy, GoodRx, and other patient access programs.

What safety risks did Novo Nordisk highlight for Wegovy HD (NVO)?

Common adverse reactions included nausea, vomiting, and dysesthesia, reported at higher rates with HD. According to the company, events related to altered skin sensation occurred in 22% of Wegovy HD patients versus 6% with 2.4 mg and 0.3% with placebo.

Who is eligible to start Wegovy HD (NVO) 7.2 mg for obesity treatment?

Wegovy HD is for adults with obesity who have tolerated 2.4 mg for at least 4 weeks and need further weight reduction. According to the company, it should be used with reduced calorie diet and increased physical activity as adjunct therapy.

How did Wegovy HD (NVO) compare to Wegovy 2.4 mg and placebo in STEP UP?

Wegovy HD showed greater weight reduction (~21% vs ~18% for 2.4 mg and ~2% for placebo, efficacy estimand). According to the company, the trial enrolled 1,407 adults without diabetes and measured outcomes at 72 weeks.

FDA approves Novo Nordisk's new Wegovy® HD injection, delivering the highest weight loss to date for a Wegovy® injection, adding to its already expansive clinical profile